AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Coherus Oncology, Inc.
Video analysis: CHRS
All videosNo video analysis for this stock yet. Request one from our team.
News: CHRS
BlackRock Inc. Takes $16.80 Million Position in Coherus Oncology, Inc. $CHRS
BlackRock Inc. bought a new stake in shares of Coherus Oncology, Inc. (NASDAQ: CHRS) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,003,316 shares of the biotechnology company's stock, valued at approximately $16,805,000. BlackRock Inc. owned about
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company's common stock as of 5:00 p.m.
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology Q2 Earnings Call Highlights
Coherus Oncology NASDAQ: CHRS said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise.
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of $0.08. This compares to a loss of $0.34 per share a year ago.
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October public disclosure of data sets with sufficient maturity – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
REDWOOD CITY, Calif. , July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Starting at 5:00 p. m.
